OncoSec Announces Initiation of a Phase 2 Study at the Moffitt Cancer Center to Evaluate the Combination of TAVO plus OPDIVO® as Neoadjuvant Therapy for Melanoma

Aug 27, 2020 8:30am EDT

OncoSec to Present at the LD 500 Virtual Conference on September 2, 2020

Aug 25, 2020 8:30am EDT

OncoSec Medical Incorporated Announces Pricing of Public Offering

Aug 16, 2020 11:55pm EDT

OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock

Aug 14, 2020 8:42pm EDT

OncoSec to Present at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020

Aug 10, 2020 8:30am EDT

OncoSec Appoints Kellie Malloy Foerter as Chief Operating Officer

Jul 27, 2020 9:00am EDT

OncoSec’s Novel COVID-19 Vaccine Candidate Featured in ‘Straight Talk’ Program by NBC TV in Portland, Oregon

Jul 13, 2020 9:00am EDT

OncoSec to be Featured in "Grand Rounds: a Webinar in Biotech and Specialty Pharma," Webinar Hosted by Alliance Global Partners

Jul 09, 2020 9:00am EDT

OncoSec Set to Join Russell Microcap® Index

Jun 24, 2020 9:00am EDT

OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II

Jun 22, 2020 9:05am EDT